title: Cabazitaxel for the treatment of castration-resistant prostate cancer.
abstract: Treatment with docetaxel-based chemotherapy results in improved survival in patients with metastatic castration-resistant prostate cancer. However, all patients eventually develop progressive disease associated with poor outcomes. In this article, we discuss the available second-line therapeutic options following docetaxel, with a special focus on cabazitaxel, which is the first agent to yield extended survival as second-line therapy following docetaxel. Cabazitaxel, a novel semi-synthetic taxane, is effective even in docetaxel-resistant model systems. Recently, results of the Phase III TROPIC trial demonstrated improved survival with cabazitaxel plus prednisone compared with mitoxantrone and prednisone in patients with progressive metastatic castration-resistant prostate cancer, following prior docetaxel, which led to approval by the US FDA.
authors.affiliation: University of Utah, Salt Lake City, Utah, UT, USA.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018938:Caco-2 Cells; D002369:Castration; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D018922:HL-60 Cells; D006801:Humans; D007941:Leukemia P388; D008297:Male; D051379:Mice; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D016019:Survival Analysis; D043823:Taxoids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D043823:Taxoids; C552428:cabazitaxel